^
Association details:
| Biomarker: | NTRK3 fusion |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/30/2020
Excerpt:
Gastrointestinal Stromal Tumors: Useful in certain circumstances…Larotrectinib or entrectinib (for NTRK gene-fusion GISTs)…
Title:
New sarcoma drug approved for use in England
Excerpt:
We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
Source:
Title:
151 - Activity and safety of larotrectinib in adult patients with TRK fusion cancer: an expanded data set
Published date:
09/03/2020
Excerpt:
Adults (aged ≥18 y) with TRK fusion cancer treated in three larotrectinib clinical trials (NCT02122913, NCT02576431, and NCT02637687) were analyzed….Tumor types included thyroid cancer (22%), salivary gland cancer (19%), soft tissue sarcoma (16%), lung cancer (12%), colon cancer (7%), melanoma (5%), breast cancer (5%), GIST (3%), and 9 other types (≤2% each). TRK fusions involved NTRK1 (43%), NTRK2 (3%), and NTRK3 (54%)...The ORR was 71% (95% CI 62-79): 10% complete response, 60% partial response (2% pending confirmation), 16% stable disease, 9% progressive disease, 3% not determined.
Source:
Title:
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
Published date:
09/02/2020
Excerpt:
The ORR with larotrectinib in adult and pediatric patients with sarcoma harboring an NTRK fusion was 74% (95% CI 52–90) and 94% (95% CI 82–99), respectively. Objective responses were observed in patients with soft tissue sarcomas, GISTs, and infantile fibrosarcoma.
DOI:
10.1016/j.annonc.2020.08.2232
Source:
Title:
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.
Published date:
05/13/2020
Excerpt:
116 adults (median age: 56 y, range 19–84 y; 53% female) with TRK fusion cancer were treated. Tumor types included thyroid cancer (22%), salivary gland cancer (19%), soft tissue sarcoma (16%), lung cancer (12%), colon cancer (7%), melanoma (5%), breast cancer (5%), GIST (3%), and 9 other types (≤2% each). NTRK fusions involved NTRK1 (43%), NTRK2 (3%), and NTRK3 (54%)....larotrectinib demonstrated robust and durable tumor-agnostic efficacy and favorable safety, supporting NTRK gene fusion testing in patients with solid tumors of any type.
DOI:
10.1200/JCO.2020.38.15_suppl.3610
